AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2009
Jan 20, 2009
33390_dirs_2009-01-20_0cec33f8-4bc3-44d1-9ef6-0d47c454fd70.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2009-01-09
Reporting Person: Irish Stephanie Rast (Sr. VP, CFO, Treasurer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Restricted Common Stock | 40000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | $0.331 | 2015-02-01 | Common Stock (960) | Direct | |
| Employee Stock Option (Right to Buy) | $4.7329 | 2015-12-29 | Common Stock (9238) | Direct | |
| Employee Stock Option (Right to Buy) | $25.50 | 2016-12-18 | Common Stock (10000) | Direct | |
| Employee Stock Option (Right to Buy) | $30.65 | 2017-01-30 | Common Stock (11000) | Direct | |
| Employee Stock Option (Right to Buy) | $5.76 | 2018-01-03 | Common Stock (17405) | Direct | |
| Employee Stock Option (Right to Buy) | $1.02 | 2018-09-18 | Common Stock (17405) | Direct |
Footnotes
F1: These shares are represented by restricted stock units. 50% of such shares vest upon approval by the FDA of the NDA for iloperidone, Vanda Pharmaceuticals Inc.'s lead product candidate, and 50% of such shares vest on December 31, 2009. Upon a change of control of Vanda Pharmaceuticals Inc., 100% of the unvested restricted stock units will vest upon the consummation of the change in control.
F2: Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to an additional 2.08333% of the aggregate shares each month thereafter.
F3: The option vests each month with respect to 2.0833% of the aggregate option share total.